Partner David Rosen was quoted in an Inside Health Policy article on January 22, 2014 titled “Generic Drug Industry Prioritizes Challenge to New Labeling Rule in 2014.” The article discusses the top priority for the generic drug industry in 2014 which will be combating a new regulation aimed at requiring generic drugmakers to make labeling changes to reflect new safety information. Rosen was quoted saying, “I think it’s going to be a pretty big deal.”
People
Related News
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."
June 5, 2025
In the News
Michael Bennett and Zack Flagel Explore Pro Tennis Antitrust Battle
Foley & Lardner LLP attorneys Michael Bennett and Zack Flagel assess the antitrust litigation embroiling professional tennis in their LawInSport article, "Break(ing) Point? The Antitrust Battle that Could Transform Professional Tennis."
June 4, 2025
In the News
Foley Attorneys Explore IP Considerations for AI-Generated Logos
Foley & Lardner LLP attorneys Von Bryant, Norm Rich, and Alex Liederman authored the Bloomberg Law article, "AI-Generated Logos Require Careful Steps to Protect IP Rights."